Board Meeting31 Jul 2026, 06:11 pm
SMS Pharma Board Approves Q1 FY27 Results, AGM, MD Re-appointment
AI Summary
SMS Pharmaceuticals Ltd's Board of Directors met on July 31, 2026, approving the standalone and consolidated un-audited financial results for the first quarter ended June 30, 2026. The company reported total income of ₹20,870.93 Lakhs and a profit before tax of ₹2,814.42 Lakhs for the quarter. The 38th Annual General Meeting is scheduled for September 23, 2026. Key decisions also included the re-appointment of Mr. Ramesh Babu Potluri as Chairman and Managing Director for five years, subject to shareholder approval, and approval to provide a loan of up to ₹50 Crores to its subsidiary, SMS Peptides Private Limited.
Key Highlights
- Q1 FY27 un-audited results approved with ₹20,870.93 Lakhs total income.
- Mr. Ramesh Babu Potluri re-appointed as CMD for 5 years.
- AGM scheduled for September 23, 2026; book closure from Sep 17-23.
- Loan of up to ₹50 Crores approved for subsidiary SMS Peptides.
- Dividend record date set for September 16, 2026.
Price Impact
More from SMSPHARMA